Abacavir

CLINICAL USE

Nucleoside reverse transcriptase inhibitor:

  • Used for HIV infection in combination with other antiretroviral drugs

    DOSE IN NORMAL RENAL FUNCTION

    600 mg daily in 1 or 2 divided doses

    PHARMACOKINETICS

  • Molecular weight                           :(daltons)286.3 (670.7 as sulphate)
  • %Protein binding                           :49
  • %Excreted unchanged in urine     : 2
  • Volume of distribution (L/kg)       :0.8
  • half-life – normal/ESRD (hrs)      :1.5/Unchanged

    • DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Unknown dialysability. Dose as in normal renal function
  • HD                             : Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   : Not dialysed. Dose as in normal renal function
  • CAV/VVHD      : Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs Antivirals: concentration reduced by tipranavir

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia